Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule

BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology

Related Keywords

Boston ,Massachusetts ,United States ,Ukraine ,Stephens Yoder , ,Society For Immunotherapy Of Cancer ,Pieris Pharmaceuticals ,Company Quarterly Reports On Form ,Nasdaq ,Company Annual Report On Form ,Exchange Commission ,Pieris Pharmaceuticals Inc View ,Securities Exchange ,Pieris Pharmaceuticals Inc ,Annual Meeting ,Looking Statements ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Reports ,Relations Contact ,Inc View ,Pieris ,Pharmaceuticals ,Nnounces ,Billion ,Milestone ,Rom ,Seagen ,Initiation ,Hase ,Trial ,D228 ,Bispecific ,Olecule ,